🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Germline Mutations

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. NCT05378204NA25 sites📍 Bordeaux📍 Caen📍 Clermont-Ferrand Institut Claudius Regaud · Tests: Main study:, Sub-study: Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cediranib, Ceralasertib, Olaparib PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC NCT06533384Phase 31 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Ca… Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency NCT06090669Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: TruSight Oncology, imatinib Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer NCT02280161n/a1 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: cytology specimen collection procedure Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation NCT05806515Phase 2133 sites📍 Anchorage📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Biospecimen Collection, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study NCT01247597n/a2 sites📍 Bethesda📍 Rockville National Cancer Institute (NCI) Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 NCT03296826n/a1 site📍 Okayama Translational Research Center for Medical Innovation, Kobe,… Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants NCT07019155n/a1 site📍 Bethesda National Cancer Institute (NCI) Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 NCT03830229n/a1 site📍 Bethesda National Cancer Institute (NCI) Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS NCT06886672n/a2 sites📍 Pavia📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation NCT04890613Phase 18 sites📍 Santa Monica📍 Tampa📍 Boston Senhwa Biosciences, Inc. · Tests: CX-5461 Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer NCT04903782n/a3 sites📍 Newcastle📍 Sydney📍 Sydney Sydney Children's Hospitals Network · Tests: Family-based whole genome sequencing Population Based Germline Testing for Early Detection and Prevention of Cancer NCT07498829NA1 site📍 London Queen Mary University of London · Tests: Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) a… The Cancer of the Pancreas Screening-5 CAPS5)Study NCT02000089Phase 39 sites📍 New Haven📍 Baltimore📍 Boston Johns Hopkins University · Tests: Secretin, MRI, Tumor marker gene test with CA19-9 Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene. NCT06022016NA5 sites📍 Bordeaux📍 Limoges📍 Marseille Institut Claudius Regaud · Tests: For each person (index case or related) included in this study: Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries NCT05769517n/a1 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: Germinal BRCA Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study NCT05576389Phase 21 site📍 Beijing Peking University People's Hospital · Tests: Camrelizumab+Fluzoparib Natural History Study of CADASIL NCT05072483n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) · Tests: MRI Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer NCT05485766Phase 23 sites📍 Gifu📍 Okayama📍 Tokyo Okayama University · Tests: Pembrolizumab, Paclitaxel, Carboplatin, Olaparib, Definitive Surgery Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma NCT05960773Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Decitabine/cedazuridine A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment NCT01994057n/a1 site📍 Guangzhou Sun Yat-sen University Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation NCT05983991NA24 sites📍 Angers📍 Bordeaux📍 Caen Institut Claudius Regaud · Tests: Biological samples (blood and bone marrow samples). Germline Genetic Testing of the TP53 Gene NCT07419893n/a1 site📍 Milan European Institute of Oncology PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness NCT04995198n/a3 sites📍 Baltimore📍 New York📍 Seattle Prostate Cancer Clinical Trials Consortium Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome NCT04431024n/a1 site📍 Bethesda National Cancer Institute (NCI) Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes NCT03058588n/a1 site📍 Brescia Azienda Socio Sanitaria Territoriale degli Spedali Civili d… · Tests: Analysis with molecular biology Early Diagnosis of High-grade Serous Epithelial Ovarian Cancer Through the Analysis of DNA Derived From Pap Test Smear. NCT07556562NA1 site📍 Roma Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: RRSO (risk-reducing salpingo- oophorectomy) or RRS (risk-reducing salpingectomy) The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation. NCT05097274n/a1 site📍 London Institute of Cancer Research, United Kingdom · Tests: MRI pelvis or CT imaging under clinical management for Pr Ca, Whole body bone scan imaging, PET-CT imaging Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer NCT07436312NA3 sites📍 Avignon📍 Rennes📍 Villejuif Gustave Roussy, Cancer Campus, Grand Paris · Tests: educational workshop on nutrition + additional intervention on UPF tool and how to use it
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy